title: Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register.
abstract: About 50% of UK patients with beta-thalassaemia major die before the age of 35 years, mainly because conventional iron-chelation therapy is too burdensome for full adherence. Patients require an individually-tailored treatment plan incorporating new, more tolerable approaches.
authors.forename: B
authors.initials: B
authors.lastname: Modell
authors.forename: M
authors.initials: M
authors.lastname: Khan
authors.forename: M
authors.initials: M
authors.lastname: Darlison
mesh_terms: D000293:Adolescent; D000328:Adult; D002614:Chelating Agents / Q000627:therapeutic use*; D015913:Chelation Therapy; D002648:Child; D015331:Cohort Studies; D003676:Deferoxamine / Q000627:therapeutic use*; D006801:Humans; D007501:Iron; D010349:Patient Compliance; D012042:Registries; D016019:Survival Analysis; D006113:United Kingdom / Q000453:epidemiology; D017086:beta-Thalassemia / Q000188:drug therapy* / Q000401:mortality*
chemical_list: D002614:Chelating Agents; D007501:Iron; D003676:Deferoxamine